Zacks Research Boosts Earnings Estimates for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research upped their Q2 2025 EPS estimates for shares of Gilead Sciences in a research note issued on Thursday, January 16th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of $1.75 per share for the quarter, up from their previous forecast of $1.72. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.86 EPS, FY2025 earnings at $7.12 EPS, Q3 2026 earnings at $2.19 EPS, Q4 2026 earnings at $2.03 EPS and FY2026 earnings at $7.55 EPS.

A number of other analysts have also recently weighed in on GILD. Piper Sandler increased their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Mizuho raised their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Wells Fargo & Company upped their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Up 0.2 %

GILD opened at $91.84 on Monday. Gilead Sciences has a one year low of $62.07 and a one year high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market capitalization of $114.46 billion, a P/E ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. The business’s 50-day simple moving average is $91.75 and its 200-day simple moving average is $84.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the company posted $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock worth $42,130,461 in the last quarter. 0.29% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences by 0.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock worth $5,887,000 after purchasing an additional 522 shares during the last quarter. Seven Eight Capital LP acquired a new position in Gilead Sciences in the second quarter worth about $525,000. AE Wealth Management LLC increased its holdings in Gilead Sciences by 11.7% in the second quarter. AE Wealth Management LLC now owns 29,796 shares of the biopharmaceutical company’s stock valued at $2,044,000 after buying an additional 3,124 shares during the last quarter. Summit Trail Advisors LLC raised its stake in Gilead Sciences by 37.7% during the second quarter. Summit Trail Advisors LLC now owns 17,105 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 4,683 shares in the last quarter. Finally, Kowal Investment Group LLC lifted its holdings in Gilead Sciences by 4.2% during the 2nd quarter. Kowal Investment Group LLC now owns 4,384 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 176 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.